Telormedix, is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. The Company’s lead product, TMX-101, is currently in a Phase II clinical trial for the treatment of CIS (carcinoma in situ) in the bladder. In addition, Telormedix is developing novel TLR7-targeted agonists. The Company was founded in 2007 and is backed by an international consortium of venture capitalists including Aravis Venture (Basel, Switzerland) and Proquest Investments (Princeton-San Diego, USA).
The Company is located in Bioggio, Switzerland.